{"prompt": "['SPIMM-301 Version 4.0', '15 June 2018', 'Termination of the clinical development for elamipretide in subjects with PMM.', 'PART 1', \"Screening Period: Screening will begin with the subject's signature of the informed consent form\", '(ICF) and will last a minimum of 7 days to a maximum of 28 days. Subjects not previously enrolled', 'in SPIMM-300, however, may have a longer screening period for review by the Adjudication', 'Committee to determine their eligibility for study enrollment. Subjects will undergo Screening', 'procedures as described in the PART 1 Schedule of Assessments (Appendix 1) and will be trained', 'and instructed to complete the PMMSA daily during the Screening Period, in an electronic or paper', 'diary, in order to characterize their baseline disease status and to assess compliance. Subjects who', 'complete Screening and continue to meet all trial requirements, including all Inclusion Criteria and', 'none of the Exclusion Criteria, may be randomized (stratified by the subclassification of the genetic', \"abnormality determined to be the primary cause of the subject's PMM [DiMauro 2003] as determined\", 'by the Adjudication Committee) and enter the Treatment Period.', 'Treatment Period: The Treatment Period will begin on the day of the Baseline Visit, which is defined', 'as Day 1, and lasts for 24 weeks. Subjects (and caregivers if needed) will be trained on the procedure', 'for administration of the elamipretide delivery system (the investigational medicinal product [IMP]', '[elamipretide or placebo], the elamipretide pen injector, and needle) and recording of the location', '(injection in the abdomen, rotating around the four abdominal quadrants, or other appropriate location', '[after Investigator consultation with the Sponsor]) and time (at approximately the same time each day', '[e.g., early morning, noon, or early afternoon]) of the IMP administration daily in the electronic or', 'paper diary. An elamipretide delivery system training kit and checklist will be provided to the clinical', 'site to assist in training. At the Baseline Visit, following completion of all Baseline procedures', 'described in the PART 1 Schedule of Assessments, subjects or trained caregivers will administer IMP', 'at the clinical site. On non-visit days, subjects (or trained caregivers) will administer the IMP daily', 'during the Treatment Period. The subject will return to the clinical site for the Week 4, Week 12, and', 'Week 24 Visits for assessments, to administer the IMP (subject or trained caregiver), and to return all', 'used IMP supplies. During the Treatment Period, subjects will continue to follow all trial', 'requirements, including recording the location and time of the IMP administration daily and', 'completing the PMMSA daily. The Treatment Period will conclude with a visit to the clinical site at', 'the Week 24 Visit when subjects will return all trial-related supplies.', 'At the Week 24 Visit, if the subject confirms they are willing and able to continue to adhere to trial', 'requirements and the Investigator determines the subject meets the Continuation Criteria the subject', 'may continue into Part 2. If the subject continues into PART 2, the subject will continue (or start, for', 'subjects treated with placebo in PART 1) elamipretide therapy the day of the Week 24 Visit (using', 'the PART 2 supply of IMP) and continue trial activities as described in the PART 2 Schedule of', 'Assessments (Appendix 2). Subjects who will not continue into PART 2 will not be administered', 'IMP and will enter the PART 1 Follow-Up Period.', 'For all subjects, it is the intent that subjects who discontinue IMP (at any time) for any reason will', 'continue to be followed for all protocol-planned trial visits through the completion of the PART 1', 'Treatment Period, and will have all endpoints (including efficacy) collected accordingly. In the', 'interest of the subject, subjects who withdraw consent or are withdrawn from the trial by the', 'investigator should be encouraged to complete an Early Discontinuation Visit as soon as possible and', 'an effort should be made to complete and report the observations as thoroughly as possible up to the', 'date of withdrawal.', 'PART 1 Follow-Up Period (for subjects not continuing into PART 2): The PART 1 Follow-Up Period', 'will begin after completion of the Week 24 Visit and will last for 4 weeks. Subjects will return to the', 'Stealth Bio Therapeutics Inc.', 'CONFIDENTIAL', '6']['SPIMM-301 Version 4.0', '15 June 2018', 'clinical site for the PART 1 End-of-Trial Visit for final safety assessments, as described in the PART', '1 Schedule of Assessments, and return all remaining trial-related supplies not previously returned.', 'PART 2', 'While there is no screening period for PART 2, subjects continuing into PART 2 must meet the', 'PART 2 Continuation Criteria. Subjects who decide not to continue in the PART 2 at the PART 1', 'Week 24 Visit are not eligible to participate in PART 2.', 'Treatment Period: The Treatment Period will begin on the day of the PART 1 Week 24 Visit (at the', 'administration of IMP) using the PART 2 supply of IMP. Subjects (or trained caregivers) will', 'administer the IMP daily during the Treatment Period. The subject will return to the clinical site for', 'the Week 28, Week 36, and Week 48 Visits for assessments, to administer the IMP (subject or trained', 'caregiver), and to return all used IMP supplies. Additional visits will occur every 24 weeks for the', 'remainder of the Treatment Period, with phone calls to the subject every 12 weeks between clinical', 'site visits. During the Treatment Period, subjects will continue to follow all trial requirements.', 'In the interest of the subject, subjects who withdraw consent or are withdrawn from the trial by the', 'investigator should be encouraged to complete an Early Discontinuation Visit as soon as possible and', 'an effort should be made to complete and report the observations as thoroughly as possible up to the', 'date of withdrawal.', 'PART 2 Follow-Up Period: The PART 2 Follow-Up Period will begin after completion of the Week', '168 Visit and will last for 4 weeks. Subjects will continue to follow all trial requirements. Subjects', 'will return to the clinical site for the PART 2 End-of-Trial Visit for final safety assessments, as', 'described in the PART 2 Schedule of Assessments, and return all remaining trial-related supplies not', 'previously returned.', 'Number of subjects (planned): Approximately 202 subjects will be randomized.', 'SPIMM-301 Eligibility Criteria', 'A subject must meet all of the following Inclusion Criteria at the Baseline Visit to be eligible for', 'inclusion in the SPIMM-301 trial:', '1. Willing and able to provide a signed informed consent form (ICF) prior to participation in', 'any trial-related procedures.', '2. Agrees and is able to adhere to the trial requirements for the length of the trial, including the', 'use of the elamipretide delivery system.', '3. Subject is >16 and 80 years of age. In Germany, subjects must be >18 years of age.', '4. Enrolled (signed ICF) in SPIMM-300 or have prior approval from the Sponsor to enroll', 'without SPIMM-300 participation.', '5. Diagnosed with PMM in the opinion of the Investigator, consisting of:', 'a. Molecular genetic abnormality of the mitochondrial respiratory chain, and', 'b.', 'Subject reported symptoms (i.e., exercise intolerance, fatigue, muscle weakness) or', 'physical examination findings of myopathy that are the predominant symptoms of the', \"subject's mitochondrial respiratory chain disorder.\", \"6. The subject's molecular genetic abnormality is consistent with PMM as confirmed by the\", 'Adjudication Committee.', '7. Women of childbearing potential must agree to use 1 of the following methods ofbirth', 'control from the date they sign the ICF until 28 days after the last dose of TIMP:', 'Stealth Bio Therapeutics Inc.', 'CONFIDENTIAL', '7']\n\n###\n\n", "completion": "END"}